MedicinemedRxiv
Heuristic editor, no API keyVerdict: NotablePlasma eMTBR-tau as a robust biomarker for Alzheimer's disease tangle pathology up to 10 years before death
Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring.
Caveats
- Not randomized: its findings are associations.
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologic change (ADNC) and predominantly reflects the burden and anatomical progression of tangle pathology but not amyloid plaque load despite being most elevated in amyloid-positive symptomatic individuals. Plasma eMTBR-tau was significantly more accurate than plasma p-tau217 in classifying Braak staging and ADNC statuses at autopsy. Importantly, neuropathologic classification by plasma eMTBR-tau remained high (AUC=0.91-0.95) even when increasing intervals between blood collection and death up to a decade, while maintaining superior sensitivity and specificity over p-tau217. Higher baseline plasma eMTBR-tau was associated with worse cognition cross-sectionally and longitudinally predicted faster worsening. These results were replicated in a living cohort with in vivo tangle and plaque neuroimaging. Plasma eMTBR-tau concordance with tau neuroimaging was up to 94%, suggesting surrogacy. Together, plasma eMTBR-tau captures biological signatures of Braak staging and ADNC over a prolonged pre-mortem window, highlighting potential for early disease detection, biological staging, prognosis and therapeutic development.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 10% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ███░░ 3 | 20% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | ███░░ 3 | 32% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ███░░ 3 | 8% | A genuinely new approach to an open problem. |
| Trajectory | ███░░ 3 | 5% | A clear path to scale. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we report); gains (outperforms); novelty (open problem); verification (experimental validation, independent replication); scale (scalable, efficient); stakes (mortality, major disease, prevention or cure). Red flags: not randomized.
How the score was computed
- Merit
- 6.0 / 10
- Adjusted merit
- 5.0 / 10
- Attention
- 0%
- Freshness
- 80%
- Citations0 (reference 20, via semantic-scholar, Oct 6, 2026, 06:17 UTC)